Login to Your Account



Gilman-led Arrakis lands $38M series A round

By Michael Fitzhugh
Staff Writer

Monday, February 27, 2017

Arrakis Therapeutics Inc., a company seeking to develop a pipeline of RNA-targeted small molecules for neurology, oncology and rare genetic disorders, has completed a $38 million series A financing.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription